CN1850230A - Chinese medicine composition for treating osteoporosis and preparing method - Google Patents
Chinese medicine composition for treating osteoporosis and preparing method Download PDFInfo
- Publication number
- CN1850230A CN1850230A CNA2006100573634A CN200610057363A CN1850230A CN 1850230 A CN1850230 A CN 1850230A CN A2006100573634 A CNA2006100573634 A CN A2006100573634A CN 200610057363 A CN200610057363 A CN 200610057363A CN 1850230 A CN1850230 A CN 1850230A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- water
- solution
- add
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine composition for effectively curing osteoporosis and its related diseases and its preparation process. It is made up by using 11 Chinese medicinal materials of cooked rehmannia root, cornus fruit, Chinese yam, epimedium, alisma tuber and others through a certain preparation process. It can be made into tablet, oral liquor, granules and injection, etc.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation method thereof and method of quality control, osteoporotic Chinese medicine composition of particularly a kind of treatment and preparation method thereof and method of quality control.
Background technology
Along with the aging of population, the osteoporosis sickness rate increases day by day, has caused the attention of national governments.World Health Organization (WHO) is being decided to be " world's osteoporosis day " annual October 20, theme as " government action " as 1998, the social of this disease is described, theme as in 2000 " to your skeleton investment ", this main body continues up to now, and prevention and status and the effect of treatment osteoporosis in health care are described.
Osteoporosis is a kind of general metabolism osteopathia, shows as bone mineral content and reduces, and the dimension fine texture of bone changes, and the toughness of bone reduces, and microtrauma just can be fractured, and osteoporotic character, pathological change and serious consequence have been described.
Osteoporosis is from morbidity, treatment and social 5 characteristics are arranged.That is: sickness rate height (male is about 20%, and the postmenopausal women 60～70 years old was up to 2/3 more than 1/3,80 years old); Pathogenic factor it be unclear that (how because of many fruits); The Therapeutic Method multiformity; The mortality rate height (repeatedly, multi-section position fracture, due to complication, mortality rate is 15%～20%); Cost high (need long-term treatment, bring heavy burden for family and society).
The osteoporotic medicine present situation of western medicines in treatment, from the understanding of Chinese and western medicine to the osteoporosis morbidity, because two kinds of guiding theory of Chinese and western medicine are different with theoretical system, western medicine (modern medicine) is mainly from the research of osteoporotic bone pathologic angle, think middle-aged and elderly people, the osteoblast active function reduces, the osteoclast activity increased functionality, bone resorption is greater than bone formation, thus the generation osteoporosis.In view of the above, the development of medicine mainly is at osteoclast or osteoblast and promotion bone mineralising, can be divided into three major types to existing western medicine medicine, suppresses the medicine of osteoclast activity: as calcitonin, diphosphonate, sex hormone drug that is:; Activate the active medicine of osteoblast: as fluoride, parathyroid hormone etc.; Promote bone mineralising medicine: various calcium preparation, vitamin D and activation preparation thereof, how method D
3, calcitriol etc.
Chinese medicine is from the morbidity of function of five internal organs understanding osteoporosis, and is deficient as kidney,liver,spleen, and based on " kidney ", and Chinese medicine is thought " kidney governing bones store essential substances ", " the kidney providing essence-QI to the bone ", " the kidney being in charge of bone and marrow ".Similar osteoporotic title has in the Chinese medicine: bone fistula, bone are withered, rheumatism involving the bone, bone shrinkage etc.In view of the above, the Chinese traditional treatment osteoporosis is controlled from the internal organs opinion, because the old people suffers from a deficiency of the kidney more, the kidney invigorating method is the osteoporotic main rule of treatment of treatment.The development of anti-bone pine pharmaceutical composition of the present invention promptly is under instruction of Chinese Medicine theory, at patient's card, carries out that macroscopic view is integrally-regulated to be set upright, and the microcosmic topical therapeutic is eliminating evil, brings into play the characteristic and the advantage of Chinese medicine, reaches the purpose for the treatment of both the principal and secondary aspects of a disease.
Summary of the invention
The object of the invention is to provide a kind of Chinese medicine composition and formulation preparation method thereof, and another purpose of the present invention is to provide the method for quality control and the purposes of this Chinese medicinal composition preparation.
The present invention seeks to be achieved through the following technical solutions:
The crude drug of Chinese medicine composition of the present invention is composed as follows:
Radix Rehmanniae Preparata 20-60 weight portion Fructus Corni 10-50 weight portion
Herba Epimedii 10-50 weight portion Rhizoma Dioscoreae 10-50 weight portion
Rhizoma Alismatis 10-50 weight portion Cortex Moutan 5-40 weight portion
Fructus Lycii 20-60 weight portion Herba Cistanches 20-60 weight portion
Semen Cuscutae 10-50 weight portion Poria 10-50 weight portion
Concha Ostreae 30-90 weight portion.
The preferred weight proportioning of above-mentioned raw materials medicine is as follows:
Radix Rehmanniae Preparata 40 weight portion Fructus Corni 35 weight portions
Herba Epimedii 30 weight portion Rhizoma Dioscoreaes 25 weight portions
Rhizoma Alismatis 40 weight portion Cortex Moutans 20 weight portions
Fructus Lycii 40 weight portion Herba Cistanches 35 weight portions
Semen Cuscutae 25 weight portion Poria 30 weight portions
Concha Ostreae 60 weight portions.
The preferred weight proportioning of above-mentioned raw materials medicine is as follows:
Radix Rehmanniae Preparata 25 weight portion Fructus Corni 45 weight portions
Herba Epimedii 15 weight portion Rhizoma Dioscoreaes 40 weight portions
Rhizoma Alismatis 25 weight portion Cortex Moutans 35 weight portions
Fructus Lycii 30 weight portion Herba Cistanches 55 weight portions
Semen Cuscutae 15 weight portion Poria 45 weight portions
Concha Ostreae 35 weight portions.
The preferred weight proportioning of above-mentioned raw materials medicine is as follows:
Radix Rehmanniae Preparata 55 weight portion Fructus Corni 15 weight portions
Herba Epimedii 45 weight portion Rhizoma Dioscoreaes 20 weight portions
Rhizoma Alismatis 40 weight portion Cortex Moutans 15 weight portions
Fructus Lycii 55 weight portion Herba Cistanches 25 weight portions
Semen Cuscutae 45 weight portion Poria 20 weight portions
Concha Ostreae 85 weight portions.
Above traditional Chinese medicinal composition raw materials is pressed the pharmaceutics common process, adds conventional adjuvant, can be prepared into clinical acceptable any dosage form, includes but not limited to following dosage form: capsule, pill, tablet, granule, oral liquid or injection.
The concrete preparation technology of the present composition is as follows:
Get Fructus Corni, Cortex Moutan, add alcohol reflux 1-3 time, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 1-3 time, filter, the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, reclaim ethanol, and the simmer down to thick paste, add conventional adjuvant, make capsule, pill, tablet, granule, oral liquid or injection according to a conventional method.
The preferred for preparation technology of the present composition is as follows:
Get Fructus Corni, Cortex Moutan, add alcohol reflux 2 times, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 3 times, filter, and the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, and reclaim ethanol, and the simmer down to thick paste, add conventional adjuvant, make granule according to a conventional method.
Quality determining method of the present invention comprises following discrimination method and/or content assaying method
Discrimination method comprises a kind of and/or several in the following discriminating:
A. get this drug combination preparation 12g, porphyrize is put in the tool plug conical flask, and the jolting that adds diethyl ether extracts twice, and each 40ml filters, and merging filtrate volatilizes, and residue adds dehydrated alcohol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 20: 5: 8: 30 cyclohexane extraction-chloroform-ethyl acetate-water is placed 24h below 10 ℃ upper strata liquid was developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to dry by the fire to the speckle colour developing at 110 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
B. get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to about 3ml, as need testing solution; Other gets the icariine reference substance, adds methanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; According to the thin layer chromatography test, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, the subnatant of placing 24h below 10 ℃ with 13: 7: 2 chloroform-methanol-water is developing solvent, launches, and takes out, dry, spray is with the acid liquor ferri trichloridi of 5% hydrochloric acid; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C. get Fructus Lycii control medicinal material 2g, add water 20ml, reflux, extract, 15 minutes is put coldly, filters, and filtrate is put in the separatory funnel, and the ether solution evaporate to dryness is collected in the 20ml that adds diethyl ether extraction, and residue adds dehydrated alcohol 1ml makes dissolving, in contrast medical material solution; Get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to 3ml, as need testing solution; In need testing solution, add alkali alumina 1g, jolting, water bath method, residue add dehydrated alcohol 2ml jolting, get supernatant as need testing solution.According to the thin layer chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developing solvent with 10: 15: 10 cyclohexane extraction-ethyl acetate-chloroforms, launch, take out, dry, put under the 365nm ultra-violet lamp and inspect; In the test sample chromatograph, with control medicinal material chromatograph relevant position on, show the speckle of same color;
D. get this drug combination preparation 12g, add water 20ml and make moisteningly, add 30 ℃ of-60 ℃ of petroleum ether 50ml, supersound process 20 minutes, leave standstill, inclining petroleum ether, volatilizes or the low temperature evaporate to dryness, and residue adds acetone 1ml dissolving, as need testing solution, other gets red phenol reference substance, adds acetone and makes the solution that every 1ml contains 5mg, in contrast product solution; According to thin layer chromatography test, draw need testing solution 10 μ l and reference substance solution 5 μ l, put respectively in same be on the silica gel g thin-layer plate of binding agent with the sodium carboxymethyl cellulose, be developing solvent with 3: 1 hexamethylene ring-ethyl acetates, launch, taking-up is dried; Spray is heated to clear spot with the acid ferric chloride ethanol of 5% hydrochloric acid liquid; In the test sample chromatograph with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Content assaying method in the method for quality control is as follows:
According to high effective liquid chromatography for measuring;
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; The 30:70 acetonitrile-water is a mobile phase, and the detection wavelength is 270nm, and number of theoretical plate should be not less than 5000 by the icariine peak;
The preparation of reference substance solution: precision takes by weighing at 105 ℃ of icariine reference substances that are dried to constant weight an amount of, adds dissolve with methanol and makes into the solution that every 1ml contains 0.018mg, in contrast product solution; The preparation of need testing solution: get this drug combination preparation 0.17g, the accurate title, decide, and puts in the tool plug triangular flask, the accurate methanol 25ml that adds, close plug claims to decide weight, power 300W, frequency 25KHz supersound process 30min is put cold, weigh, supply the weight that subtracts mistake with methanol, shake up, filter, discard filtrate just, precision is measured subsequent filtrate 10ml and is put in the evaporating dish, water bath method, and residue water 10ml gradation is transferred in the separatory funnel, with water-saturated n-butanol shaking out 5 times, each 10ml divides and gets n-butanol layer, adds freshly prepared 3ml → 100ml ammonia spirit 10ml, jolting washing 1 time, it is standby that branch is got n-butanol extracting liquid; Water saturation n-butanol extraction 5 time of ammonia layer, each 10ml collects n-butanol extracting liquid, incorporates in the aforementioned n-butanol extracting liquid, and water bath method, residue, filter with 0.45 μ m microporous filter membrane to 5ml with methanol constant volume, and filtrate is as need testing solution; Algoscopy: accurate reference substance solution and each 20 μ l of need testing solution of drawing, inject chromatograph of liquid, measure peak area, calculate by external standard method, promptly.
Following experiment and embodiment are used to further specify but are not limited to the present invention.
Experimental example: clinical research experiment
Adopt randomized, double-blind, positive drug (GUSHUKANG KELIJI) parallel control, pharmaceutical composition 319 examples wherein of the present invention, GUSHUKANG KELIJI 100 examples.The comprehensive therapeutic effect result shows: medicine composite for curing osteoporosis comprehensive therapeutic effect total effective rate 1. of the present invention is 84.95%, and obvious effective rate is 46.39%; The total effective rate of treatment of control group osteoporosis is 72.00%, and obvious effective rate is 38.00%, and test group and matched group relatively have significant difference.2. pharmaceutical composition of the present invention is 97.18% to the disease comprehensive therapeutic effect total effective rate that Chinese medical discrimination belongs to the deficiency of the liver and kindey card, and the control obvious effective rate is 56.43%; The total effective rate of the traditional Chinese medical science disease comprehensive therapeutic effect of treatment of control group osteoporosis is 95.00%, and the control obvious effective rate is 41.00%, and test group and matched group comparing difference have significance.3. pharmaceutical composition of the present invention is 98.43% to the total effective rate that Chinese medical discrimination belongs to the primary symptom comprehensive therapeutic effect of deficiency of the liver and kindey card, and the control obvious effective rate is 70.54%; Total effective rate to traditional Chinese medical science disease primary symptom comprehensive therapeutic effect after the treatment of control group is 94.00%, and the control obvious effective rate is 53.00%, and test group has significance with matched group than difference.See Table 1-3.
Table 1: two groups of osteoporosis comprehensive therapeutic effects (PP) [n (%)]
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate | Statistic | The P value |
| The test group matched group | 319 100 | 148(46.39) 34(34.00) | 123(38.56) 38(38.00) | 48(15.05) 28(28.00) | 84.95％ 72.00％ | χ 2＝9.741 | 0.008 |
Table 2: two groups of tcm syndrome comprehensive therapeutic effects (PP) [n (%)]
| Group | The example number | Clinic control | Produce effects | Effectively | Invalid | Total effective rate | Statistic | The P value |
| The test group matched group | 319 100 | 25(7.84) 1(1.00) | 155(48.59) 40(40.00) | 130(40.75) 53(53.00) | 9(2.82) 5(5.00) | 97.18％ 95.00％ | χ 2＝11.706 | 0.008 |
Table 3: two groups of cardinal symptoms, sign comprehensive therapeutic effect (PP) [n (%)]
| Group | The example number | Clinic control | Produce effects | Effectively | Invalid | Total effective rate | Statistic | The P value |
| The test group matched group | 319 100 | 54(16.93) 8(8.00) | 171(53.61) 45(45.00) | 89(27.90) 41(41.00 ) | 5(1.57) 6(6.00) | 98.43％ 94.00％ | χ 2＝15.104 | 0.002 |
Efficacy result to the clinical symptom of osteoporosis shows: 1. to whole body osteodynia or lumbar vertebrae pain and soreness of the waist and knees two primary symptoms, the comparison of two groups of treatment front and back integration drop-out values: test group and matched group each stage primary symptom integrated value after treatment all obviously descends than before treating, to improving primary symptom good effect is arranged all, difference has significance.But test group is fast than matched group in whole body osteodynia or lumbar vertebrae pain integration fall, and difference has significance, shows that pharmaceutical composition of the present invention obviously is better than matched group to the therapeutic effect of whole body osteodynia or lumbar vertebrae pain.2. two groups of treatment front and back time disease score values relatively: test group and matched group each stage time disease integrated value after treatment all has good effect all than obvious decline before the treatment to improving time disease, and difference has significance.Kowtow aspect pain or the tenderness improving breast, lumbar vertebra body, after two end courses of treatment of treatment, test group integration fall is big than matched group, and difference has significance, the result shows that pharmaceutical composition of the present invention kowtows the clinical sign aspect of pain or tenderness to improving breast, lumbar vertebra body, and curative effect is better than matched group.See Table 4-6.
Table 4: treat situation (d ± s) (n) that compares between the primary symptom integration drop-out value group of back for two groups
| Project | Group (n) | Medication drop-out value in January | Medication drop-out value in February | Finish drop-out value a course of treatment | Medication drop-out value in April | Medication drop-out value in May | Finish drop-out value two courses of treatment |
| Whole body osteodynia or lumbar vertebrae pain | Test group (319) matched group (100) statistic P value | 0.29±0.74 0.15±0.66 Z＝-1.618 0.106 | 0.81±1.08 0.55±0.98 Z＝-1.877 0.060 | 1.24±1.20 0.90±1.14 Z＝-2.382 0.017 | 1.55±1.23 1.38±1.29 Z＝-1.090 0.276 | 2.03±1.46 1.76±1.43 Z＝-1.467 0.142 | 2.55±1.54 2.10±1.57 Z＝-2.425 0.015 |
| Soreness of the waist and knees | Test group (319) matched group (100) statistic P value | 0.50±0.88 0.42±0.82 Z＝-0.858 0.391 | 0.97±1.07 0.98±1.04 Z＝-0.009 0.993 | 1.34±1.18 1.46±1.10 Z＝-0.945 0.345 | 1.85±1.36 1.76±1.15 Z＝-0.474 0.635 | 2.24±1.44 2.19±1.23 Z＝-0.378 0.705 | 2.71±1.48 2.69±1.47 Z＝-0.349 0.727 |
Table 5: treat situation (d ± s) (n) that compares between time disease integration drop-out value group of back for two groups
| Project | Group (n) | Medication drop-out value in January | Medication drop-out value in February | Finish drop-out value a course of treatment | Medication drop-out value in April | Medication drop-out value in May | Finish drop-out value two courses of treatment |
| Breast, lumbar vertebra body are kowtowed, tenderness | Test group (319) matched group (100) statistic P value | 0.19±0.47 0.13±0.46 Z＝-1.073 0.283 | 0.38±0.55 0.30±0.50 Z＝-1.326 0.185 | 0.60±0.64 0.51±0.66 Z＝-1.200 0.230 | 0.79±0.73 0.65±0.69 Z＝-1.668 0.095 | 0.99±0.80 0.83±0.74 Z＝-1.895 0.058 | 1.24±0.77 1.03±0.78 Z＝-2.230 0.026 |
| Lower limb is soft unable | Test group (319) matched group (100) statistic P value | 0.23±0.47 0.10±0.36 Z＝-2.601 0.009 | 0.46±0.58 0.38±0.55 Z＝-1.129 0.259 | 0.69±0.64 0.61±0.57 Z＝-0.934 0.350 | 0.91±0.74 0.72±0.62 Z＝-2.075 0.038 | 1.12±0.82 0.90±0.75 Z＝-2.148 0.032 | 1.34±0.86 1.16±0.76 Z＝-1.759 0.079 |
| Can not be prudent | Test group (319) matched group (100) statistic P value | 0.17±0.41 0.27±0.51 Z＝-2.254 0.024 | 0.41±0.59 0.50±0.63 Z＝-1.267 0.205 | 0.65±0.72 0.67±0.70 Z＝-0.346 0.729 | 0.84±0.76 0.78±0.75 Z＝-0.538 0.591 | 1.03±0.84 0.99±0.82 Z＝-0.292 0.771 | 1.21±0.85 1.15±0.83 Z＝-0.646 0.518 |
| Vertigo and tinnitus | Test group (319) matched group (100) statistic P value | 0.26±0.53 0.27±0.53 Z＝-0.098 0.992 | 0.56±0.66 0.48±0.67 Z＝-0.675 0.500 | 0.78±0.76 0.67±0.74 Z＝-1.149 0.251 | 0.98±0.82 0.86±0.79 Z＝-1.220 0.222 | 1.10±0.85 0.96±0.78 Z＝-1.406 0.160 | 1.22±0.83 1.03±0.80 Z＝-1.961 0.050 |
Table 6: compare (d ± s) (n) between the group of treatment back primary symptom time disease integrated integral drop-out value
| Group (n) | Medication drop-out value in January | Medication drop-out value in February | Finish drop-out value a course of treatment | Medication drop-out value in April | Medication drop-out value in May | Finish drop-out value two courses of treatment |
| Test group (319) matched group (100) statistic P value | 1.93±1.73 1.63±1.67 Z＝-1.506 0.132 | 4.11±2.47 3.74±2.25 Z＝-1.286 0.199 | 6.04±3.15 5.52±2.82 Z＝-1.224 0.221 | 7.76±3.86 6.92±3.58 Z＝-1.864 0.062 | 9.40±4.68 8.55±4.44 Z＝-1.577 0.115 | 11.27±4.83 10.15±4.74 Z＝-2.034 0.042 |
Each position bone density measurement result before and after the treatment is shown: 1. lumbar spine bmd changes comparable situation before and after the treatment: test group treatment back lumbar spine bmd obviously raises, and difference has significance; Lumbar vertebra variable density there was no significant difference after the treatment of control group.It is 66.67% that the test group lumbar spine bmd improves effective percentage, and it is 60.53% that the matched group lumbar spine bmd improves effective percentage.2. femoral neck bone density measure situation of change compares before and after the treatment: test group treatment back femoral neck bone density obviously raises, and difference has significance; Femoral neck bone variable density there was no significant difference after the treatment of control group.It is 76.51% that test group femoral neck bone density is improved effective percentage, and it is 65.12% that matched group femoral neck bone density is improved effective percentage.Relatively, difference has significance, shows that pharmaceutical composition of the present invention obviously is better than contrasting medicine to femoral neck bone density rising effect between two groups.3. the situation of treatment front and back greater trochanter of femur bone density measurement value relatively: two groups of treatment backs of test group and matched group greater trochanter bone density obviously raises, and relatively preceding with treatment, difference has significance.After treating two courses of treatment, test group greater trochanter bone density rising amplitude is big than matched group, and two groups relatively, and difference has significance, illustrates that pharmaceutical composition of the present invention obviously is better than matched group to the effect that the greater trochanter of femur bone density raises.It is 88.89% that test group is improved effective percentage to the greater trochanter of femur bone density, and the effective percentage of matched group is 50.00%, and test group obviously is better than matched group to the total effective rate that improves of greater trochanter bone density value.4. Word triquetrum density measurement situation of change before and after the treatment: two groups of treatment backs of test group and matched group Word triquetrum density all obviously improves, and compares before the treatment, and difference has significance.The effective percentage that test group Word triquetrum density is improved is 64.58%, and the effective percentage that the matched group bone density is improved is 63.64%.See Table 7-10.
Table 7: two groups of treatment back lumbar vertebra density values improve the comparison [n (%)] of curative effect
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate | Statistic | The P value |
| The test group matched group | 156 38 | 65(41.67) 16(42.11) | 39(25.00) 7(18.42) | 52(33.33) 15(39.47) | 66.67％ 60.53％ | χ 2＝0.893 | 0.640 |
Table 8: two groups of treatment back femoral neck bone density values improve the comparison [n (%)] of curative effect
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate | Statistic | The P value |
| The test group matched group | 149 43 | 80(53.69) 12(27.91) | 34(22.82) 16(37.21) | 35(23.49) 15(34.88) | 76.51％ 65.12％ | χ 2＝8.947 | 0.011 |
Table 9: two groups of treatment back greater trochanter bone density values improve the comparison [n (%)] of curative effect
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate | Statistic | The P value |
| The test group matched group | 106 30 | 59(77.78) 14(50.00) | 20(11.11) 9(0.00) | 27(11.11) 7(50.00) | 88.89％ 50.00& | χ 2＝1.754 | 0.416 |
Table 10: two groups of treatment Vee formation bone density values improve the comparison [n (%)] of curative effect
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate | Statistic | The P value |
| The test group matched group | 283 89 | 165(52.08) 51(40.91) | 43(12.50) 20(22.73) | 75(35.42) 18(36.36) | 64.58％ 63.64％ | χ 2＝3.196 | 0.202 |
Following embodiment all can realize the effect of above-mentioned experimental example.
Embodiment 1: the preparation of granule
Radix Rehmanniae Preparata 40kg Fructus Corni 35kg Herba Epimedii 30kg Rhizoma Dioscoreae 25kg
Rhizoma Alismatis 40kg Cortex Moutan 20kg Fructus Lycii 40kg Herba Cistanches 35kg
Semen Cuscutae 25kg Poria 30kg Concha Ostreae 60kg
Get Fructus Corni, Cortex Moutan, add alcohol reflux 2 times, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 3 times, filter, and the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, and reclaim ethanol, and the simmer down to thick paste, add adjuvant, stir evenly, granulate, drying, promptly.
Embodiment 2: the preparation of capsule
Radix Rehmanniae Preparata 25kg Fructus Corni 45kg Herba Epimedii 15kg Rhizoma Dioscoreae 40kg
Rhizoma Alismatis 25kg Cortex Moutan 35kg Fructus Lycii 30kg Herba Cistanches 55kg
Semen Cuscutae 15kg Poria 45kg Concha Ostreae 35kg
Get Fructus Corni, Cortex Moutan, add alcohol reflux 3 times, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 2 times, filter, and the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, and reclaim ethanol, and the simmer down to thick paste, add conventional adjuvant, according to common process, make capsule.
Embodiment 3: the preparation of pill
Radix Rehmanniae Preparata 55kg Fructus Corni 15kg Herba Epimedii 45kg Rhizoma Dioscoreae 20kg
Rhizoma Alismatis 40kg Cortex Moutan 15kg Fructus Lycii 55kg Herba Cistanches 25kg
Semen Cuscutae 45kg Poria 20kg Concha Ostreae 85kg
Get Fructus Corni, Cortex Moutan, add alcohol reflux 2 times, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 2 times, filter, and the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, and reclaim ethanol, and the simmer down to thick paste, add conventional adjuvant, according to common process, make pill.
Embodiment 4: the preparation of tablet
Radix Rehmanniae Preparata 30kg Fructus Corni 45kg Herba Epimedii 20kg Rhizoma Dioscoreae 45kg
Rhizoma Alismatis 25kg Cortex Moutan 40kg Fructus Lycii 35kg Herba Cistanches 55kg
Semen Cuscutae 20kg Poria 45kg Concha Ostreae 55kg
Get Fructus Corni, Cortex Moutan, add alcohol reflux 3 times, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 3 times, filter, and the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, and reclaim ethanol, and the simmer down to thick paste, add conventional adjuvant, according to common process, make tablet.
Embodiment 5: the preparation of oral liquid
Radix Rehmanniae Preparata 40kg Fructus Corni 35kg Herba Epimedii 30kg Rhizoma Dioscoreae 25kg
Rhizoma Alismatis 40kg Cortex Moutan 20kg Fructus Lycii 40kg Herba Cistanches 35kg
Semen Cuscutae 25kg Poria 30kg Concha Ostreae 60kg
Above compositions adds conventional adjuvant, according to common process, makes oral liquid.
Embodiment 6: the discrimination method in the quality testing of granule
A. get this drug combination preparation 12g, porphyrize is put in the tool plug conical flask, and the jolting that adds diethyl ether extracts twice, and each 40ml filters, and merging filtrate volatilizes, and residue adds dehydrated alcohol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 20: 5: 8: 30 cyclohexane extraction-chloroform-ethyl acetate-water is placed 24h below 10 ℃ upper strata liquid was developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to dry by the fire to the speckle colour developing at 110 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
B. get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to about 3ml, as need testing solution; Other gets the icariine reference substance, adds methanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; According to the thin layer chromatography test, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, the subnatant of placing 24h below 10 ℃ with 13: 7: 2 chloroform-methanol-water is developing solvent, launches, and takes out, dry, spray is with the acid liquor ferri trichloridi of 5% hydrochloric acid; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C. get Fructus Lycii control medicinal material 2g, add water 20ml, reflux, extract, 15 minutes is put coldly, filters, and filtrate is put in the separatory funnel, and the ether solution evaporate to dryness is collected in the 20ml that adds diethyl ether extraction, and residue adds dehydrated alcohol 1ml makes dissolving, in contrast medical material solution; Get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to 3ml, as need testing solution; In need testing solution, add alkali alumina 1g, jolting, water bath method, residue add dehydrated alcohol 2ml jolting, get supernatant as need testing solution.According to the thin layer chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developing solvent with 10: 15: 10 cyclohexane extraction-ethyl acetate-chloroforms, launch, take out, dry, put under the 365nm ultra-violet lamp and inspect; In the test sample chromatograph, with control medicinal material chromatograph relevant position on, show the speckle of same color;
D. get this drug combination preparation 12g, add water 20ml and make moisteningly, add 30 ℃ of-60 ℃ of petroleum ether 50ml, supersound process 20 minutes, leave standstill, inclining petroleum ether, volatilizes or the low temperature evaporate to dryness, and residue adds acetone 1ml dissolving, as need testing solution, other gets red phenol reference substance, adds acetone and makes the solution that every 1ml contains 5mg, in contrast product solution; According to thin layer chromatography test, draw need testing solution 10 μ l and reference substance solution 5 μ l, put respectively in same be on the silica gel g thin-layer plate of binding agent with the sodium carboxymethyl cellulose, be developing solvent with 3: 1 hexamethylene ring-ethyl acetates, launch, taking-up is dried; Spray is heated to clear spot with the acid ferric chloride ethanol of 5% hydrochloric acid liquid; In the test sample chromatograph with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Embodiment 7: the content assaying method in the quality testing of oral liquid
According to high effective liquid chromatography for measuring;
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; 30: 70 acetonitrile-waters are mobile phase, and the detection wavelength is 270nm, and number of theoretical plate should be not less than 5000 by the icariine peak;
The preparation of reference substance solution: precision takes by weighing at 105 ℃ of icariine reference substances that are dried to constant weight an amount of, adds dissolve with methanol and makes into the solution that every 1ml contains 0.018mg, in contrast product solution; The preparation of need testing solution: get this drug combination preparation 0.17g, the accurate title, decide, and puts in the tool plug triangular flask, the accurate methanol 25ml that adds, close plug claims to decide weight, power 300W, frequency 25KHz supersound process 30min is put cold, weigh, supply the weight that subtracts mistake with methanol, shake up, filter, discard filtrate just, precision is measured subsequent filtrate 10ml and is put in the evaporating dish, water bath method, and residue water 10ml gradation is transferred in the separatory funnel, with water-saturated n-butanol shaking out 5 times, each 10ml divides and gets n-butanol layer, adds freshly prepared 3ml → 100ml ammonia spirit 10ml, jolting washing 1 time, it is standby that branch is got n-butanol extracting liquid; Water saturation n-butanol extraction 5 time of ammonia layer, each 10ml collects n-butanol extracting liquid, incorporates in the aforementioned n-butanol extracting liquid, and water bath method, residue, filter with 0.45 μ m microporous filter membrane to 5ml with methanol constant volume, and filtrate is as need testing solution; Algoscopy: accurate reference substance solution and each 20 μ l of need testing solution of drawing, inject chromatograph of liquid, measure peak area, calculate by external standard method, promptly.The every gram icariine C of this product
33H
40O
15Must not be less than 0.75mg.
Embodiment 8: the quality determining method of capsule
A. get this drug combination preparation 12g, porphyrize is put in the tool plug conical flask, and the jolting that adds diethyl ether extracts twice, and each 40ml filters, and merging filtrate volatilizes, and residue adds dehydrated alcohol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 20: 5: 8: 30 cyclohexane extraction-chloroform-ethyl acetate-water is placed 24h below 10 ℃ upper strata liquid was developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to dry by the fire to the speckle colour developing at 110 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
B. get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to about 3ml, as need testing solution; Other gets the icariine reference substance, adds methanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; According to the thin layer chromatography test, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 13: 7: 2 chloroform-methanol-water is placed the subnatant of 24h below 10 ℃ be developing solvent, launches, and takes out, dry, spray is with the acid liquor ferri trichloridi of 5% hydrochloric acid; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C. get Fructus Lycii control medicinal material 2g, add water 20ml, reflux, extract, 15 minutes is put coldly, filters, and filtrate is put in the separatory funnel, and the ether solution evaporate to dryness is collected in the 20ml that adds diethyl ether extraction, and residue adds dehydrated alcohol 1ml makes dissolving, in contrast medical material solution; Get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to 3ml, as need testing solution; In need testing solution, add alkali alumina 1g, jolting, water bath method, residue add dehydrated alcohol 2ml jolting, get supernatant as need testing solution.According to the thin layer chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developing solvent with 10: 15: 10 cyclohexane extraction-ethyl acetate-chloroforms, launch, take out, dry, put under the 365nm ultra-violet lamp and inspect; In the test sample chromatograph, with control medicinal material chromatograph relevant position on, show the speckle of same color;
D. get this drug combination preparation 12g, add water 20ml and make moisteningly, add 30 ℃ of-60 ℃ of petroleum ether 50ml, supersound process 20 minutes, leave standstill, inclining petroleum ether, volatilizes or the low temperature evaporate to dryness, and residue adds acetone 1ml dissolving, as need testing solution, other gets red phenol reference substance, adds acetone and makes the solution that every 1ml contains 5mg, in contrast product solution; According to thin layer chromatography test, draw need testing solution 10 μ l and reference substance solution 5 μ l, put respectively in same be on the silica gel g thin-layer plate of binding agent with the sodium carboxymethyl cellulose, be developing solvent with 3: 1 hexamethylene ring-ethyl acetates, launch, taking-up is dried; Spray is heated to clear spot with the acid ferric chloride ethanol of 5% hydrochloric acid liquid; In the test sample chromatograph with the corresponding position of reference substance chromatograph on, show the speckle of same color.
According to high effective liquid chromatography for measuring;
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; 30: 70 acetonitrile-waters are mobile phase, and the detection wavelength is 270nm, and number of theoretical plate should be not less than 5000 by the icariine peak;
The preparation of reference substance solution: precision takes by weighing at 105 ℃ of icariine reference substances that are dried to constant weight an amount of, adds dissolve with methanol and makes into the solution that every 1ml contains 0.018mg, in contrast product solution; The preparation of need testing solution: get this drug combination preparation 0.17g, the accurate title, decide, and puts in the tool plug triangular flask, the accurate methanol 25ml that adds, close plug claims to decide weight, power 300W, frequency 25KHz supersound process 30min is put cold, weigh, supply the weight that subtracts mistake with methanol, shake up, filter, discard filtrate just, precision is measured subsequent filtrate 10ml and is put in the evaporating dish, water bath method, and residue water 10ml gradation is transferred in the separatory funnel, with water-saturated n-butanol shaking out 5 times, each 10ml divides and gets n-butanol layer, adds freshly prepared 3ml → 100ml ammonia spirit 10ml, jolting washing 1 time, it is standby that branch is got n-butanol extracting liquid; Water saturation n-butanol extraction 5 time of ammonia layer, each 10ml collects n-butanol extracting liquid, incorporates in the aforementioned n-butanol extracting liquid, and water bath method, residue, filter with 0.45 μ m microporous filter membrane to 5ml with methanol constant volume, and filtrate is as need testing solution; Algoscopy: accurate reference substance solution and each 20 μ l of need testing solution of drawing, inject chromatograph of liquid, measure peak area, calculate by external standard method, promptly.
The every gram icariine C of this product
33H
40O
15Must not be less than 0.75mg.
Claims (10)
1, the osteoporotic Chinese medicine composition of a kind of treatment is characterized in that the crude drug of this Chinese medicine composition consists of:
Radix Rehmanniae Preparata 20-60 weight portion Fructus Corni 10-50 weight portion
Herba Epimedii 10-50 weight portion Rhizoma Dioscoreae 10-50 weight portion
Rhizoma Alismatis 10-50 weight portion Cortex Moutan 5-40 weight portion
Fructus Lycii 20-60 weight portion Herba Cistanches 20-60 weight portion
Semen Cuscutae 10-50 weight portion Poria 10-50 weight portion
Concha Ostreae 30-90 weight portion.
2, Chinese medicine composition as claimed in claim 1 is characterized in that this traditional Chinese medicinal composition raw materials weight proportion is as follows:
Radix Rehmanniae Preparata 40 weight portion Fructus Corni 35 weight portions
Herba Epimedii 30 weight portion Rhizoma Dioscoreaes 25 weight portions
Rhizoma Alismatis 40 weight portion Cortex Moutans 20 weight portions
Fructus Lycii 40 weight portion Herba Cistanches 35 weight portions
Semen Cuscutae 25 weight portion Poria 30 weight portions
Concha Ostreae 60 weight portions.
3, Chinese medicine composition as claimed in claim 1 is characterized in that this traditional Chinese medicinal composition raw materials weight proportion is as follows:
Radix Rehmanniae Preparata 25 weight portion Fructus Corni 45 weight portions
Herba Epimedii 15 weight portion Rhizoma Dioscoreaes 40 weight portions
Rhizoma Alismatis 25 weight portion Cortex Moutans 35 weight portions
Fructus Lycii 30 weight portion Herba Cistanches 55 weight portions
Semen Cuscutae 15 weight portion Poria 45 weight portions
Concha Ostreae 35 weight portions.
4, Chinese medicine composition as claimed in claim 1 is characterized in that this traditional Chinese medicinal composition raw materials weight proportion is as follows:
Radix Rehmanniae Preparata 55 weight portion Fructus Corni 15 weight portions
Herba Epimedii 45 weight portion Rhizoma Dioscoreaes 20 weight portions
Rhizoma Alismatis 40 weight portion Cortex Moutans 15 weight portions
Fructus Lycii 55 weight portion Herba Cistanches 25 weight portions
Semen Cuscutae 45 weight portion Poria 20 weight portions
Concha Ostreae 85 weight portions.
5,, it is characterized in that said composition makes capsule, pill, tablet, granule, oral liquid or injection as the arbitrary described Chinese medicine composition of claim 1-4.
6, as the preparation method of claim 1,2,3 or 4 described Chinese medicine compositions, it is characterized in that this method is: get Fructus Corni, Cortex Moutan, add alcohol reflux 1-3 time, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 1-3 time, filter, the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, reclaim ethanol, and the simmer down to thick paste, add conventional adjuvant, make capsule, pill, tablet, granule, oral liquid or injection according to a conventional method.
7, the preparation method of Chinese medicine composition as claimed in claim 6 is characterized in that this method is: get Fructus Corni, Cortex Moutan, add alcohol reflux 2 times, merge extractive liquid, filters; Nine flavors such as residue and all the other Radix Rehmanniae Preparata decoct with water 3 times, filter, and the filtrate condensed cream, precipitate with ethanol filters, and filtrate and above-mentioned alcohol extract merge, and reclaim ethanol, and the simmer down to thick paste, add conventional adjuvant, make granule according to a conventional method.
8, the quality determining method of Chinese medicine composition as claimed in claim 5 is characterized in that this method comprises a kind of and/or several in the following discriminating:
A. get this drug combination preparation 12g, porphyrize is put in the tool plug conical flask, and the jolting that adds diethyl ether extracts twice, and each 40ml filters, and merging filtrate volatilizes, and residue adds dehydrated alcohol 1ml makes dissolving, as need testing solution; Other gets the ursolic acid reference substance, adds dehydrated alcohol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; Test according to thin layer chromatography, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with 20: 5: 8: 30 cyclohexane extraction-chloroform-ethyl acetate-water is placed 24h below 10 ℃ upper strata liquid was developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to dry by the fire to the speckle colour developing at 110 ℃; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
B. get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to about 3ml, as need testing solution; Other gets the icariine reference substance, adds methanol and makes the solution that every 1ml contains 0.5mg, in contrast product solution; According to the thin layer chromatography test, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, the subnatant of placing 24h below 10 ℃ with 13: 7: 2 chloroform-methanol-water is developing solvent, launches, and takes out, dry, spray is with the acid liquor ferri trichloridi of 5% hydrochloric acid; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
C. get Fructus Lycii control medicinal material 2g, add water 20ml, reflux, extract, 15 minutes is put coldly, filters, and filtrate is put in the separatory funnel, and the ether solution evaporate to dryness is collected in the 20ml that adds diethyl ether extraction, and residue adds dehydrated alcohol 1ml makes dissolving, in contrast medical material solution; Get this drug combination preparation 12g, put in the tool plug conical flask, add water 30ml, after placement makes molten loosing, add ethanol 100ml, silica gel for chromatography 10g shakes up, supersound process 15 minutes filters, and filtrate is put and steamed in the water-bath to about 10ml, add water 20ml and be transferred in the separatory funnel, add dilute hydrochloric acid 2ml, with ethyl acetate 30ml extraction, collect ethyl acetate liquid, wash twice with water, each 20ml, discard water lotion, ethyl acetate liquid is put and is steamed in the tepidarium to 3ml, as need testing solution; In need testing solution, add alkali alumina 1g, jolting, water bath method, residue add dehydrated alcohol 2ml jolting, get supernatant as need testing solution; According to the thin layer chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developing solvent with 10: 15: 10 cyclohexane extraction-ethyl acetate-chloroforms, launch, take out, dry, put under the 365nm ultra-violet lamp and inspect; In the test sample chromatograph, with control medicinal material chromatograph relevant position on, show the speckle of same color;
D. get this drug combination preparation 12g, add water 20ml and make moisteningly, add 30 ℃ of-60 ℃ of petroleum ether 50ml, supersound process 20 minutes, leave standstill, inclining petroleum ether, volatilizes or the low temperature evaporate to dryness, and residue adds acetone 1ml dissolving, as need testing solution, other gets red phenol reference substance, adds acetone and makes the solution that every 1ml contains 5mg, in contrast product solution; According to thin layer chromatography test, draw need testing solution 10 μ l and reference substance solution 5 μ l, put respectively in same be on the silica gel g thin-layer plate of binding agent with the sodium carboxymethyl cellulose, be developing solvent with 3: 1 hexamethylene ring-ethyl acetates, launch, taking-up is dried; Spray is heated to clear spot with the acid ferric chloride ethanol of 5% hydrochloric acid liquid; In the test sample chromatograph with the corresponding position of reference substance chromatograph on, show the speckle of same color.
9, the quality determining method of Chinese medicine composition as claimed in claim 5 is characterized in that this method comprises following assay:
According to high effective liquid chromatography for measuring;
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; 30: 70 acetonitrile-water is mobile phase, and the detection wavelength is 270nm, and number of theoretical plate should be not less than 5000 by the icariine peak;
The preparation of reference substance solution: precision takes by weighing at 105 ℃ of icariine reference substances that are dried to constant weight an amount of, adds dissolve with methanol and makes into the solution that every 1ml contains 0.018mg, in contrast product solution; The preparation of need testing solution: get this drug combination preparation 0.17g, the accurate title, decide, and puts in the tool plug triangular flask, the accurate methanol 25ml that adds, close plug claims to decide weight, power 300W, frequency 25KHz supersound process 30min is put cold, weigh, supply the weight that subtracts mistake with methanol, shake up, filter, discard filtrate just, precision is measured subsequent filtrate 10ml and is put in the evaporating dish, water bath method, and residue water 10ml gradation is transferred in the separatory funnel, with water-saturated n-butanol shaking out 5 times, each 10ml divides and gets n-butanol layer, adds freshly prepared 3ml → 100ml ammonia spirit 10ml, jolting washing 1 time, it is standby that branch is got n-butanol extracting liquid; Water saturation n-butanol extraction 5 time of ammonia layer, each 10ml collects n-butanol extracting liquid, incorporates in the aforementioned n-butanol extracting liquid, and water bath method, residue, filter with 0.45 μ m microporous filter membrane to 5ml with methanol constant volume, and filtrate is as need testing solution; Algoscopy: accurate reference substance solution and each 20 μ l of need testing solution of drawing, inject chromatograph of liquid, measure peak area, calculate by external standard method, promptly.
10, as the application of the arbitrary described Chinese medicine composition of claim 1-4 in preparation treatment medicine for treating osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100573634A CN1319573C (en) | 2006-03-10 | 2006-03-10 | Chinese medicine composition for treating osteoporosis and preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100573634A CN1319573C (en) | 2006-03-10 | 2006-03-10 | Chinese medicine composition for treating osteoporosis and preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850230A true CN1850230A (en) | 2006-10-25 |
| CN1319573C CN1319573C (en) | 2007-06-06 |
Family
ID=37131742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100573634A Active CN1319573C (en) | 2006-03-10 | 2006-03-10 | Chinese medicine composition for treating osteoporosis and preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1319573C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526378A (en) * | 2012-02-16 | 2012-07-04 | 丁丽曼 | Application of tree peony bark-barbary wolfberry fruit particles to preparation of hypoglycemic medicament |
| CN103083479A (en) * | 2013-03-07 | 2013-05-08 | 杨晖 | Traditional Chinese medical composition for treating postmenopausal osteoporosis |
| CN104116868A (en) * | 2014-08-14 | 2014-10-29 | 赖祥林 | Compound medicine for treating osteoporosis and preparation method thereof |
| CN105709008A (en) * | 2014-12-01 | 2016-06-29 | 邯郸制药股份有限公司 | Traditional Chinese medicine composition for treatment of gout and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1038813C (en) * | 1993-07-02 | 1998-06-24 | 周勇 | Traditional Chinese medicine for curing osteoporosis |
| CN1087619C (en) * | 1998-11-06 | 2002-07-17 | 卿多舜 | Medicines for treating osteoporosis and their preparing process |
-
2006
- 2006-03-10 CN CNB2006100573634A patent/CN1319573C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526378A (en) * | 2012-02-16 | 2012-07-04 | 丁丽曼 | Application of tree peony bark-barbary wolfberry fruit particles to preparation of hypoglycemic medicament |
| CN103083479A (en) * | 2013-03-07 | 2013-05-08 | 杨晖 | Traditional Chinese medical composition for treating postmenopausal osteoporosis |
| CN103083479B (en) * | 2013-03-07 | 2014-10-01 | 李其英 | Traditional Chinese medical composition for treating postmenopausal osteoporosis |
| CN104116868A (en) * | 2014-08-14 | 2014-10-29 | 赖祥林 | Compound medicine for treating osteoporosis and preparation method thereof |
| CN104116868B (en) * | 2014-08-14 | 2017-09-15 | 玉林市中西医结合骨科医院 | Treat thin compound medicine of bone and preparation method thereof |
| CN105709008A (en) * | 2014-12-01 | 2016-06-29 | 邯郸制药股份有限公司 | Traditional Chinese medicine composition for treatment of gout and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1319573C (en) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1806846A (en) | Chinese medicinal composition, its preparation process and quality control method | |
| CN102145106B (en) | Chinese medical composition for treating osteoporosis and granular formulation capable of tonifying kidney and invigorating blood circulation | |
| CN101062080A (en) | Medicinal composition for relieving fatigue and preparing process thereof | |
| CN1319573C (en) | Chinese medicine composition for treating osteoporosis and preparing method | |
| CN101057925B (en) | Preparation technology for 'jieguqili' capsule | |
| CN104288245B (en) | Anti-aging and constitutional pharmaceutical composition and preparation method thereof and detection method | |
| CN110013470B (en) | Application of Shenbao tablet in preparing medicine for treating sequelae of pelvic inflammatory disease | |
| CN101485872B (en) | Chinese medicinal composition for treating gastropathy as well as preparation and detection method thereof | |
| CN1284567C (en) | Medicinal liquid for treating osteoporosis and its preparation method | |
| CN114053337B (en) | Traditional Chinese medicine composition with effects of relieving spirit and resisting depression and preparation method thereof | |
| CN1891284A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| CN1923263A (en) | Traditional Chinese medicine composition, its preparing method and quality controlling means | |
| CN1899590A (en) | Gynecological Chinese patented medicine for relieving depressed liver and clearing heat, strengthening spleen and nourishing blood and its preparing method | |
| CN1289115C (en) | Immunity raising Chinese medicine and its prepn process | |
| CN1772085A (en) | Extract for treating functional indigestion and its medicine composition | |
| CN102114070B (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN102366493B (en) | Traditional Chinese medicine compound extract for treating postmenopausal osteoporosis and preparation method thereof | |
| CN1634479A (en) | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof | |
| CN103316228A (en) | Scorpio unsting wine | |
| CN103655821A (en) | Traditional Chinese medicine preparation with effects of benefiting Qi and raising Yang as well as replenishing essence and tonifying marrow and preparation method of traditional Chinese medicine preparation | |
| CN100434092C (en) | Prescription containing sweet clover component and its formulation | |
| CN1241586C (en) | Chinese medicine composition and preparing method thereof | |
| CN1294948C (en) | Medicine for boosting qi, strengthening spleen and nourishing liver and kidney and its preparation method | |
| CN103830426B (en) | One treats vasculitic Chinese medicine composition | |
| CN1583133A (en) | Effervescent tablets for bone diseases and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: HANDAN MOLUODAN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HANDAN PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 056005 No. 309 National Road, Handan Hebei Industrial Park, No. 18 Patentee after: Handan Moluodan Pharmaceutical Co., Ltd. Address before: 056005 south side of 309 National Road, hi tech Zone, Handan, Hebei Patentee before: Handan Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: HANDAN PHARMACY CO., LTD. Free format text: FORMER NAME: HANDAN MOLUODAN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 056005 No. 309 National Road, Handan Hebei Industrial Park, No. 18 Patentee after: HANDAN PHARMACEUTICAL CO., LTD. Address before: 056005 No. 309 National Road, Handan Hebei Industrial Park, No. 18 Patentee before: Handan Moluodan Pharmaceutical Co., Ltd. |